Drug insight: Angiotensin-converting-enzyme inhibitors and atrial fibrillation - Indications and contraindications

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 4, 2006, Pages 220-225

  Lévy, Samuel ^a,b  

^a School of Medicine   (France)

^b HÔPITAL NORD   (France)

Author keywords

ACE inhibitors; Atrial fibrillation; Atrial remodeling; Cardioversion; Renin angiotensin aldosterone system

Indexed keywords

AMIODARONE; ANGIOTENSIN II; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; MITOGEN ACTIVATED PROTEIN KINASE 1; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL;

ADRENERGIC ACTIVITY; ATTENUATION; CARDIOVERSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; ENZYME RELEASE; EVIDENCE BASED MEDICINE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; META ANALYSIS; METABOLIC DISORDER; NONHUMAN; OUTCOMES RESEARCH; PRESSORECEPTOR; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; VALIDATION STUDY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33645458398     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0480     Document Type: Review

References (41)

1. Cabin HS et al. (1990) Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 61: 714-717
2. Yusuf S et al. (2000) Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153
3. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 316: 1429-1435
4. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325: 293-303
5. Kjekshus J and Swedberg K (1988) Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62: 60A-66A
6. Kober L et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group (1995) A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333: 1670-1676
7. Dahlof B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003
8. Watchell K et al. (2003) Losartan reduces the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: The LIFE study [abstract]. Eur Heart J 24: 504
9. Freestone B et al. (2004) The renin-angiotensin-aldosterone system in atrial fibrillation: A new therapeutic target? J Human Hypertens 18: 461-465
10. Madrid AH et al. (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 106: 331-336
11. Maggioni AP et al. (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Val-HeFT trial. Am Heart J 149: 548-557
12. Klein HU and Goette A (2003) Blockade of atrial angiotensin II type 1 receptors: A novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 41: 2197-2204
13. Lévy S et al. (2003) International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 5: 119-122
14. Duprez DA (2004) Angiotensin II, platelets and oxidative stress. J Hypertens 22: 1085-1086
15. Boehm M and Nabel EG (2002) Angiotensin-converting enzyme 2 - a new cardiac regulator. N Engl J Med 347: 1795-1797
16. Madrid AH et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27: 1405-1410
17. Pedersen OD et al. (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100: 376-380
18. Vermes E et al. (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107: 2926-2931
19. L'Allier PL et al. (2004) Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 44: 159-164
20. Mathew JP et al.(2004) A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291: 1720-1729
21. Zaman AG et al. (2004) Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 147: 823-827
22. Ueng KC et al. (2003) Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 24: 2090-2098
23. Nakashima H et al. (2000) Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 101: 2612-2617
24. Li D et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104: 2608-2614
25. Cardin S et al. (2003) Evolution of the atrial substrate in experimental heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 60: 315-325
26. Wijffels MC et al. (1995) Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 92: 1954-1968
27. Nattel S and Li D (2000) Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 87: 440-447
28. Aime-Sempe C et al. (1999) Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34: 1577-1586
29. Weber KT et al. (1993) Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 27: 341-348
30. Li D et al. (1999) Promotion of atrial fibrillation by heart failure in dogs: Atrial remodelling of a different sort. Circulation 100: 87-95
31. Goette A et al. (2000) Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35: 1669-1677
32. Shi Y et al. (2002) Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54: 456-461
33. Tsai CT et al. (2004) Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 109: 1640-1646
34. Das UN (2005) Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 11: RA155-RA162
35. Dernellis J and Panaretou M (2004) Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25: 1100-1107
36. Maixent JM et al. (1998) Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 9: 612-617
37. Finkielstein D and Schweitzer P (2004) Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation. Am J Cardiol 93: 734-736
38. Yusuf S (2002) From the HOPE to the ONTARGET and the TRANSCEND Studies: challenges in improving prognosis. Am J Cardiol 89 (Suppl 1): S18-S25
39. Fuster V et al. (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22: 1852-1923
40. Lopez-Sendon J et al. Task Force on ACE Inhibitors of the European Society of Cardiology (2004) Expert consensus document on angiotensin-converting enzyme inhibitors in cardiovascular disease. Eur Heart J 25: 1454-1470
41. Healey JS et al. (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 45: 1832-1839